Find Clinical Trials

On this page, you will find different kinds of study results:

• A Lay summary which is a summary of clinical trial results written in an easy-to-understand way.
• A summary of results called synopsis which is written in scientific language. It is prepared for Medicines Agencies and Ethics Committees,
• A scientific publication which presents results for scientists and medical doctors.

219 Results

Protocol Code	Study Title	Active substance/Medical device	Study Phase	Therapeutic Area
CL2-05682-102	Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in…	MICRONISED PURIFIED FLAVONOID FRACTION, S005682	Phase 2	Cardiovascular Diseases
CL2-05682-099	Effects of micronised purified flavonoic fraction on microcirculation in women suffering from chronic venous disease	MICRONISED PURIFIED FLAVONOID FRACTION, S005682	Phase 2	Cardiovascular Diseases
CL1-95005-001	Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer	TIPIRACIL, TRIFLURIDINE, S095005	Phase 1	Cancers
CL1-81694-001	Phase I dose-escalation study of S 81694 administered intravenously in adult patients with advanced/metastatic solid…	S081694	Phase 1	Cancers
CL1-80881-007	An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy,…	LUCITANIB, S080881	Phase 1-2	Cancers
CL1-78454-009	Phase I dose escalation study of oral administration of Pan-Histone Deacetylase (HDAC) inhibitor S 78454…	ABEXINOSTAT, S078454	Phase 1	Cancers
CL1-78454-008	Phase I dose-escalation study of oral administration of the Histone Deacetylase (HDAC) Inhibitor S 78454…	ABEXINOSTAT, S078454	Phase 1	Cancers
CL1-78454-006	Phase I dose-escalation study of S 78454 (HDACi) p.o. in combination with FOLFOX in patients…	ABEXINOSTAT, S078454	Phase 1	Cancers
CL1-78454-005	Phase I dose-escalation study of oral administration of S 78454 given with a fixed dose…	ABEXINOSTAT, S078454	Phase 1	Cancers
CL1-78454-002	Phase I dose-escalation study of oral administration of Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in…	ABEXINOSTAT, S078454	Phase 1	Cancers
CL1-68587-003	A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have…	UCART19, S068587	Phase 1	Cancers
CL1-68587-002	Phase I, open label, dose-escalation study to evaluate the safety, expansion, persistence and biological activity…	UCART19, S068587	Phase 1	Cancers
CL1-64315-001	Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic…	S064315	Phase 1	Cancers
CL1-55746-001	Phase I dose-escalation study of oral administration of the selective Bcl2 inhibitor S55746 in patients…	S055746	Phase 1	Cancers
CL1-49076-003	Phase I/II study of oral administration of S 49076 given in combination with gefitinib in…	S049076	Phase 1-2	Cancers
CL1-49076-001	Phase I dose-escalation study of oral administration of MET Tyrosine Kinase Inhibitor S 49076 in…	S049076	Phase 1	Cancers
CL1-20098-081	Evaluation of the effect of agomelatine and escitalopram on emotions and motivation in healthy male…	AGOMELATINE, S020098	Phase 1	Neuropsychiatric Diseases
CL1-078454-018	Long-term safety study of abexinostat (S 078454) per os given as single-agent in haematological malignancies…	ABEXINOSTAT, S078454	Phase 1-2	Cancers
CL1-055746-002	Phase I dose-escalation study of the orally administrered selective Bcl-2 inhibitor S055746 as monotherapy for…	S055746	Phase 1	Cancers

Previous 1 2 … 8 9